DJSG
RARE icon

D.J. St. Germain’s Ultragenyx Pharmaceutical RARE Stock Holding History

D.J. St. Germain’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300
Closed -$9.02K – 957
2025
Q3 		$9.02K Hold
300
– – ﹤0.01% 658
2025
Q2 		$10.9K Hold
300
– – ﹤0.01% 643
2025
Q1 		$10.9K Hold
300
– – ﹤0.01% 552
2024
Q4 		$12.6K Hold
300
– – ﹤0.01% 560
2024
Q3 		$16.7K Hold
300
– – ﹤0.01% 493
2024
Q2 		$12.3K Hold
300
– – ﹤0.01% 515
2024
Q1 		$14K Hold
300
– – ﹤0.01% 519
2023
Q4 		$14.3K Hold
300
– – ﹤0.01% 520
2023
Q3 		$10.7K Hold
300
– – ﹤0.01% 525
2023
Q2 		$13.8K Buy
+300
New +$13.9K ﹤0.01% 507

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.J. St. Germain's RARE Position: Q4 2025 in Review

D.J. St. Germain sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 300 shares — an estimated $9.02K sold.

D.J. St. Germain first reported a position in RARE in Q2 2023 and held it in 10 quarters. The position peaked at $16.7K in Q3 2024. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • D.J. St. Germain reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • D.J. St. Germain sold 300 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $9.02K.
  • D.J. St. Germain first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 10 quarters.
  • D.J. St. Germain's Ultragenyx Pharmaceutical position peaked at $16.7K in Q3 2024.
  • 288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on D.J. St. Germain's 13F filing for Q4 2025, filed 29 Jan 2026.